linjc16/ctgov huggingface dataset:
Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to see if applying PRP and PPP to surgical sites and the closing incision helps prevent infection and slow wound healing.

Detailed Description
-----------------
This will be a prospective, randomized study with patients blinded to either receiving platelet-rich plasma (PRP) and platelet-poor plasma (PPP) treatment or no treatment. We hypothesize that the antimicrobial properties of PRP and barrier properties of PPP (acting like a tissue sealant) will serve to inhibit deep incisional surgical site infection and help prevent delayed wound healing within 60 days of surgery. Thus, the incidence of infection and delayed wound healing will be lower in patients receiving PRP and PPP compared to patients who do not receive PRP and PPP. However, due to clinical equipoise, we do not know for certain that PRP and PPP is truly effective. The cost of preparing PRP and PPP is substantial, and involves a blood draw that would not otherwise be done. Thus, it is important to know if this treatment is effective or not.

Official Title
-----------------
Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing After Elective Foot and Ankle Surgery in Healthy Adults

Conditions
-----------------
Elective Foot and Ankle Surgery.

Intervention / Treatment
-----------------
* Biological: PRP and PPP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective foot and ankle surgery. Exclusion Criteria: Younger than 18 years, older than 80 years of age.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Receiving PRP and PPP.<br>Administration of PRP and PPP to surgical site. | Biological: PRP and PPP<br>* Autogenous PRP and PPP<br>|
| No Intervention: Control<br>Group not receiving autogenous PRP and PPP. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative Infection and Delayed Wound Healing. | Postoperative deep incisional surgical site infection and delayed wound healing (lack of primary healing of skin edges typically with wound secretion). | Infection: 30 days after surgery. Delayed wound healing: 60 days. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Infection, delayed wound healing, platelet-rich plasma
Allogeneic Stem Cell Transplantation (ALLO-SCT) in Elderly: 17-years Retrospective GITMO Survey

Study Overview
=================
Brief Summary
-----------------
The age of patients' population is increasing every year, as the life expectancy. Thus, the incidence and prevalence of hematological cancers is increasing. In particular, acute leukemias and myelodisplastic syndromes are the most frequent diseases of the hematopoietic system. Allogeneic stem cell transplantation (allo-SCT) is the main therapeutic options for these diseases, and the number of allo-SCTs in the elderly is currently in progressive growth. This is partially due to the improvement of the allo-SCT procedure over the years, with the amelioration of donor selection, HLA typing, graft versus host disease (GVHD) and infections prophylaxis and treatment. Nevertheless, there is still an unmet clinical need, represented by the lack of extensively and detailed outcome analysis of elderly patients addressed to allo-SCT. With this aim, we planned this retrospective analysis of allo-SCTs in patients older than 60 years, within the GITMO transplant activity of the last 17 years. This study will help us in designing future prospective trials, including a comprehensive geriatric assessment of frailty, in order to address to allo-SCT those elderly who have the highest probability to achieve the best long term outcome with the lowest transplant-related mortality and morbidity.

Official Title
-----------------
Allogeneic Stem Cell Transplantation (ALLO-SCT) in Elderly: 17-years Retrospective GITMO Survey

Conditions
-----------------
Allogeneic Stem Cell Transplantation in Elderly Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
This study will enrol patients older than 60 years who received hematopoietic stem cell transplantation (HSCT) between 1st January 2000 and 31st December 2017.

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Survival | Overall Survival | 1 year | 
| Disease Free Survival | Disease Free Survival | 1 year | 
| Transplant Related Mortality | Transplant Related Mortality | 1 year | 
| Acute Graft Versus Host Disease Incidence | Acute Graft Versus Host Disease Incidence | 100 days | 
| Chronic Graft Versus Host Disease Incidence | Chronic Graft Versus Host Disease Incidence | 1 year | 
| Relapse Incidence | Relapse Incidence | 1 year |
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer

Study Overview
=================
Brief Summary
-----------------
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy. onkovis aims an economical utilization of the chemotherapeutics.The provision with adapted packaging sizes as to decrease the excess quantity to be discarded follows also this objective. Secondary objectives are the evaluation of the safety and tolerability of Doce onkovis. To this purpose data regarding co medications and adverse events are also collected.

Official Title
-----------------
Open, Multicenter Observational Study of Docetaxel Utilized in Mono- or Combination Therapy for Treatment of Breast Cancer, NSCLC, Prostate Carcinoma, Adenocarcinoma of Stomach and Advanced Squamous Cell Carcinoma of Head/Neck Region.

Conditions
-----------------
Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for Docetaxel according to the SmPC and treating physician Exclusion Criteria: according to the Docetaxel SmPC
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| carcinoma, Doce onkovis (Docetaxel)<br>treatment in mono- or combination therapy with Docetaxel of breast cancer, non-small cell lung cancer, prostata carcinoma, adenocarcinoma of the stomach and advanced squamous cell carcinoma of the head/neck region. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the quantity of Doce onkovis needed pro treatment cycle | Determine the quantity of Doce onkovis needed pro treatment cycle | the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles). | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adverse events during and after treatment | The number and kind of adverse events during and after the intra-venous application of Docetaxel will be assessed and documented. | up to 24 weeks (8 cycles) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
carcinoma, breast cancer, non-small cell lung cancer, prostata cancer, adenocarcinoma of the stomach, squamous cell carcinoma of the head and neck region, ambulant chemotherapy, treatment cycles, Docetaxel, Doce onkovis, Quantity of Docetaxel, Packaging Sizes
Hemopatch Versus No Hemopatch (Renal Transplant)

Study Overview
=================
Brief Summary
-----------------
Kidney transplantation remains one of the most common organ transplanted today but the surgical technique has changed very little from the original pelvic operation. The deceased donor renal transplant poses a particular challenge to the surgeon due to lack of detailed pre operative vascular assessment. The hemopatch is a promising new sealing synthetic hemostatIc agent with a novel dual mechanism of action that is more convenient to apply rather then using other hemostatic agents, which require warming and/or mixing.

Official Title
-----------------
A Prospective Randomized Trial of Hemopatch Versus No Hemopatch For the Intraoperative Hemostasis During Deceased Donor Renal Transplant

Conditions
-----------------
Renal Failure

Intervention / Treatment
-----------------
* Device: Hemopatch
* Device: No Hemopatch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients at least 18 years of age and capable of giving informed consent Patients scheduled for deceased donor renal transplant surgery Exclusion Criteria: Patient undergoing live related transplant surgery. Patient having uncorrectable bleeding diathesis. Any patient in the no hemopatch group requiring additional haemostatic agents for achieving hemostasis like fibrillar or surgical.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Hemopatch<br>The hemopatch is a promising new sealing synthetic hemostatic agent with a noval dual mechanism of action. The hemopatch is a polyethylene glycol coated (PEG coated) collagen patch. The PEG coating helps in rapid adhesion to the tissue surface while the collagen layer causes platelet activation and adhesion. | Device: Hemopatch<br> <br> |
| Active Comparator: Standard technique<br>Standard hemostatic agents (floseal, tisseal). | Device: No Hemopatch<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood Loss | Blood loss will be measured in ml (cc). | Baseline (Intraoperatively) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemostasis achievement | Hemostasis achievement will be measured in minutes. | Baseline (Intraoperatively) | 
| Drop in Hemoglobin | Hemoglobin will be measured in g/L (drop measured from pre-operative levels to post-operative 48 hours). | up to 48 hours postoperatively | 
| Amount of Perigraft Collection | measured in ml (with ultrasound done within 48 hours of surgery). | up to 48 hours postoperative |
Infant Glidescope® Learning Curve

Study Overview
=================
Brief Summary
-----------------
A prospective trial evaluating the learning curve associated with the use of a videolaryngoscope compared to conventional direct laryngoscopy in infants intubated by anesthesiology residents. Hypothesis: The learning curves of both instruments are equivalent.

Official Title
-----------------
Learning Curve of the Infant Glidescope® Cobalt Video Laryngoscope in Anesthesiology Residents

Conditions
-----------------
Tracheal Intubation

Intervention / Treatment
-----------------
* Device: Glidescope videolaryngoscope


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: infants under 10 kg undergoing general anesthesia and requiring tracheal intubation Exclusion Criteria: Difficult airway, severe cardiorespiratory disease, emergency surgery

Ages Eligible for Study
-----------------
Maximum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Glidescope intubation<br>Comparison of direct laryngoscopy and Glidescope videolaryngoscopy | Device: Glidescope videolaryngoscope<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to optimum visualization of the vocal cords |  | Under 2 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to tracheal intubation |  | Under 2 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
infants, general anesthesia, tracheal intubation
Accuracy of Navigation in Placement of Sacroiliac Screw

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the precision of computer-assisted navigation for hip screw implantation to conventional fixation without navigation.

Detailed Description
-----------------
Standard treatment for sacroiliac dislocations and sacroiliac fractures is placement of two screws through the iliosacral joint into the sacral ala or the body of the S1 vertebra. Correct positioning is technically demanding. Screw displacement may reduce the strength of fixation and lead to neurological complications. Secondary objectives of the study are to compare the fluoroscopy time, complications and surgery duration between the treatments.

Official Title
-----------------
Accuracy of Navigation in Placement of Sacroiliac Screw. Multicenter Randomized Controlled Trial

Conditions
-----------------
Hip Fracture

Intervention / Treatment
-----------------
* Procedure: Navigated
* Procedure: Conventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Radiologically confirmed sacroiliac dislocation or sacroiliac fracture Sacroiliac arthritis Age 18 years and more Written informed consent by patient or his/her legal representative Exclusion Criteria: Poor life expectancy (<3months) Fracture of pathologic origin History of substance abuse (recreational drugs, alcohol)within 12 months prior to screening Prisoner Currently involved in another study that precludes or complicates participation Disease or condition that would preclude accurate evaluation (e.g., significant psychiatric disease)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Navigated<br> | Procedure: Navigated<br>* Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.<br>* Other names: BrainLab Vector Vision®Trauma Navigation Software;|
| Active Comparator: Conventional<br> | Procedure: Conventional<br>* Subjects receive standard fluoroscopic placement of the sacroiliac screw.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of misplaced sacroiliac screws as evaluated by postop CT-scanning. |  | 2 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fluoroscopic time, complications and surgery duration. |  | 2 days |
Sagittal Balance Through Ages

Study Overview
=================
Brief Summary
-----------------
The parameters of the sagittal balance of the cervical, thoracic and lumbar spine vary according to the types of spino-pelvic organization (types 1-4 according to Roussouly). These parameters have been described as a function of age in previous scientific work without taking into account the pelvic anatomy (pelvic incidence and spino-pelvic organization). This work, carried out within the framework of a round table of the French Society of Spinal Surgery (SFCR), would make it possible to provide a more detailed repository of existing radiographic parameters.

Official Title
-----------------
Sagittal Balance Through Ages

Conditions
-----------------
Spinal Deformity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Minor or major subject aged 5 to 100 Subject having carried out a telecolonne or EOS type X-ray for spinal balance (low back pain, sciatica, cervico-brachial neuralgia, inequality of length of the lower limbs) in spinal surgery consultation Subject not having expressed its opposition, after information, to the re-use of its data for the purposes of this research. Exclusion criteria: Subject with surgical history, fractures, osteoporotic packing, vertebral deformation (scoliosis, kyphosis, spondylolisthesis grades 2-5), vertebral osteolysis (spondylodiscitis, tumor or metastasis). Subject who expressed his opposition to participate in the study Subject under guardianship or curatorship Subject under judicial protection

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of the radiographic parameters measured by the KEOPS software |  | files analysed retrospectily from from January 1, 2014 to December 31, 2019 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spinal Deformity, Low back pain, Sciatica, Cervico brachial neuralgia
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS

Study Overview
=================
Brief Summary
-----------------
To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy. In patients with inflammatory rheumatic disorders requiring prolonged glucocorticoid therapy, such tool could be useful to adapt first-line treatment decisions (in daily practice and in future clinical trials). The main objective of the study is to identify routine clinical, biological and DXA baseline characteristics predictive of the occurrence of clinically relevant complications of glucocorticoid therapy at 1 year, in order to propose a predictive score.

Official Title
-----------------
PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS

Conditions
-----------------
Inflammatory Rheumatism, Polymyalgia Rheumatica, Giant Cell Arteritis, Idiopathic Inflammatory Myopathies, ANCA Associated Vasculitis, Systemic Autoimmune Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Life expectancy > 1 year. Indication to initiate prolonged glucocorticoid therapy at a dosage ≥ 15 mg/day for the treatment of an inflammatory rheumatic disease. Initial treatment or relapse. Previsional treatment duration > 3 months. Exclusion Criteria: Unable to consent. Previous corticosteroid therapy in the last 3 months at a significant dosage (> 5 mg per day).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinically relevant complication of glucocorticoid therapy | The occurrence of one or more clinically relevant complication of glucocorticoid therapy during the first year of treatment, according to the Glucocorticoid Toxicity Index (items and specific list). | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life assessed through SF-36 |  | 1 year |